Description
Librela is an innovative drug for the alleviation of pain associated with osteoarthritis in dogs. The medication contains a canine monoclonal antibody (mAb) which targets nerve growth factor (NGF). This inhibits NGF-mediated cell signalling which has been demonstrated to provide relief from pain associated with osteoarthritis. The product is administered by monthly injection and has been proven to reduce pain scores in dogs with osteoarthritis.
Dosage and administration
For subcutaneous use.
Dosage and treatment schedule
- The recommended dose is 0.5-1.0 mg/kg bodyweight, once a month.
- For dogs weighing <5.0 kg aseptically withdraw 0.1 ml/kg from a single 5 mg/ml vial and administer subcutaneously.
For dogs between 5 and 60 kg administer the entire content of the vial (1 ml) according to the table below:
|
LIBRELA strength (mg) to be administered
|
|||||
|
Bodyweight (kg) of dog
|
5
|
10
|
15
|
20
|
30
|
|
5.0 – 10.0
|
1 vial
|
||||
|
10.1 – 20.0
|
1 vial
|
||||
|
20.1 – 30.0
|
1 vial
|
||||
|
30.1 – 40.0
|
1 vial
|
||||
|
40.1 – 60.0
|
1 vial
|
||||
|
60.1 – 80.0
|
2 vials
|
||||
|
80.1 – 100.0
|
1 vial
|
1 vial
|
|||
|
100.1 – 120.0
|
2 vials
|
||||
For dogs above 60 kg, the contents of more than one vial are required to administer a single dose. In those cases, withdraw the content from each required vial into the same syringe and administer as a single subcutaneous injection (2 ml).
Needles and syringes will need to be purchased separately
This is a refrigerated product and therefore will need to be sent by courier with someone available to sign for the package upon delivery. Contents must be refrigerated upon delivery.
